Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elza C de Bruin

Showing results (1-10 of 40) with videos related to

Pageof 4
Sort By:
Cancer Treatment Reviews|August 30, 2008
Apoptosis and non-apoptotic deaths in cancer development and treatment responseElza C de Bruin, Jan Paul Medema
Molecular & Cellular Oncology|June 17, 2016
Analysis of intratumor heterogeneity unravels lung cancer evolutionElza C de Bruin, Nicholas McGranahan, Charles Swanton
Genome Medicine|November 26, 2013
Intra-tumor heterogeneity: lessons from microbial evolution and clinical implicationsElza C de Bruin, Tiffany B Taylor, Charles Swanton
Genome Biology|September 16, 2014
Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicineCrispin Hiley, Elza C de Bruin, Nicholas McGranahan, et al.
Science Translational Medicine|April 17, 2015
Clonal status of actionable driver events and the timing of mutational processes in cancer evolutionNicholas McGranahan, Francesco Favero, Elza C de Bruin, et al.
Melanoma Research|April 20, 2004
c-Myc is able to sensitize human melanoma cells to diverse apoptotic triggersLucy T C Peltenburg, Elza C de Bruin, Dorothea Meersma, et al.
Scientific Reports|February 18, 2022
Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibitionTereza Vaclova, Atanu Chakraborty, James Sherwood, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2008
Epithelial human leukocyte antigen-DR expression predicts reduced recurrence rates and prolonged survival in rectal cancer patientsElza C de Bruin, Cornelis J H van de Velde, J Han J M van Krieken, et al.
Cancer Research Communications|July 2, 2024
mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of PIK3CA-Altered TumorsConstance A Sobsey, Bjoern C Froehlich, Georgia Mitsa, et al.
Plos One|May 5, 2017
Accurate detection of low prevalence AKT1 E17K mutation in tissue or plasma from advanced cancer patientsElza C de Bruin, Jessica L Whiteley, Claire Corcoran, et al.
Pageof 4

Showing results (1-10 of 40) with videos related to

Sort By:
Pageof 4
Cancer Treatment Reviews|August 30, 2008
Apoptosis and non-apoptotic deaths in cancer development and treatment responseElza C de Bruin, Jan Paul Medema
Molecular & Cellular Oncology|June 17, 2016
Analysis of intratumor heterogeneity unravels lung cancer evolutionElza C de Bruin, Nicholas McGranahan, Charles Swanton
Genome Medicine|November 26, 2013
Intra-tumor heterogeneity: lessons from microbial evolution and clinical implicationsElza C de Bruin, Tiffany B Taylor, Charles Swanton
Genome Biology|September 16, 2014
Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicineCrispin Hiley, Elza C de Bruin, Nicholas McGranahan, et al.
Science Translational Medicine|April 17, 2015
Clonal status of actionable driver events and the timing of mutational processes in cancer evolutionNicholas McGranahan, Francesco Favero, Elza C de Bruin, et al.
Melanoma Research|April 20, 2004
c-Myc is able to sensitize human melanoma cells to diverse apoptotic triggersLucy T C Peltenburg, Elza C de Bruin, Dorothea Meersma, et al.
Scientific Reports|February 18, 2022
Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibitionTereza Vaclova, Atanu Chakraborty, James Sherwood, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2008
Epithelial human leukocyte antigen-DR expression predicts reduced recurrence rates and prolonged survival in rectal cancer patientsElza C de Bruin, Cornelis J H van de Velde, J Han J M van Krieken, et al.
Cancer Research Communications|July 2, 2024
mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of PIK3CA-Altered TumorsConstance A Sobsey, Bjoern C Froehlich, Georgia Mitsa, et al.
Plos One|May 5, 2017
Accurate detection of low prevalence AKT1 E17K mutation in tissue or plasma from advanced cancer patientsElza C de Bruin, Jessica L Whiteley, Claire Corcoran, et al.
Pageof 4